...
首页> 外文期刊>Mediators of inflammation >Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM
【24h】

Construction, Expression, and Characterization of a Recombinant Immunotoxin Targeting EpCAM

机译:重组免疫毒素靶向EPCAM的构建,表达和表征

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Epithelial cell adhesion molecule (EpCAM) is a type I transmembrane glycoprotein overexpressed in human epithelioma but with relatively low expression in normal epithelial tissues. To exploit this differential expression pattern for targeted cancer therapy, an EpCAM-targeted immunotoxin was developed and its antitumor activity was investigated in vitro. An immunotoxin (scFv2A9-PE or APE) was constructed by genetically fusing a truncated form (PE38KDEL) of Pseudomonas aeruginosa exotoxin with an anti-EpCAM single-chain variable fragment (scFv). ELISA and flow cytometry were performed to verify immunotoxin (scFv2A9-PE or APE) antigen-binding activity with EpCAM. Cytotoxicity was measured by MTT assay. Confocal microscopy was used to observe its cellular localization. The results of ELISA and flow cytometry revealed that the immunotoxin efficiently recognized recombinant and natural EpCAM. Its antigen-binding activity was relatively lower than 2A9. MTT assay confirmed potent reduction in EpCAM-positive HHCC (human hepatocellular carcinoma) cell viability (IC50 50 pM). Immunofluorescence revealed that the immunotoxin localized to endoplasmic reticulum 24 h later. In conclusion, we described the development of an EpCAM-targeted immunotoxin with potent activity against tumor cells, which may lay the foundation for future development of therapeutic antibody for the treatment of EpCAM-positive tumors.
机译:上皮细胞粘附分子(EPCAM)是人上皮瘤中过表达的I型跨膜糖蛋白,但在正常上皮组织中具有相对低的表达。为了利用针对靶向癌症治疗的差异表达模式,开发了EPCAM靶向的免疫毒素,并在体外研究了其抗肿瘤活性。通过遗传融合具有抗EPCAM单链可变片段(SCFV)的截断形式(PE38KDEL)的截断形式(PE38KDEL)的截断形式(PE38KDEL)构建免疫毒素(SCFV2A9-PE或猿)。进行ELISA和流式细胞术以验证与EPCAM的免疫毒素(SCFV2A9-PE或APE)抗原结合活性。通过MTT测定法测量细胞毒性。共聚焦显微镜用于观察其细胞定位。 ELISA和流式细胞仪的结果表明,免疫毒素有效地识别重组和天然EPCAM。其抗原结合活性相对低于2a9。 MTT测定证实EPCAM阳性HHCC(人肝细胞癌)细胞活力(IC50 50 PM)的有效降低。免疫荧光显示,免疫毒素在以后24小时内局部定位成内质网。总之,我们描述了对肿瘤细胞的有效活性的EPCAM靶向免疫毒素的发展,这可能为治疗EPCAM阳性肿瘤的治疗抗体的未来发展奠定了基础。

著录项

  • 来源
    《Mediators of inflammation》 |2015年第3期|共11页
  • 作者单位

    Fourth Mil Med Univ Xijing Hosp Dept Clin Immunol Xian 710032 Peoples R China;

    Chinese Navy Gen Hosp Dept Neurol Beijing 100048 Peoples R China;

    Chinese Peoples Liberat Army Gen Hosp Dept Geriatr Gastroenterol Beijing 100853 Peoples R China;

    Fourth Mil Med Univ Dept Immunol Xian 710032 Peoples R China;

    Fourth Mil Med Univ Dept Immunol Xian 710032 Peoples R China;

    Fourth Mil Med Univ Xijing Hosp Dept Clin Immunol Xian 710032 Peoples R China;

    Chinese Navy Gen Hosp Dept Neurol Beijing 100048 Peoples R China;

    Chinese Peoples Liberat Army Gen Hosp Dept Geriatr Gastroenterol Beijing 100853 Peoples R China;

    Fourth Mil Med Univ Dept Immunol Xian 710032 Peoples R China;

    Fourth Mil Med Univ Xijing Hosp Dept Clin Immunol Xian 710032 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 病理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号